The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma):A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma

Trial Profile

The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma):A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Filanesib (Primary) ; Carfilzomib
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms FACTOR
  • Sponsors Array BioPharma
  • Most Recent Events

    • 03 Feb 2015 According to Array Biopharma media release, the company is delaying the start of patient enrollment until the binimetinib and encorafenib transactions with Novartis are closed.
    • 08 Nov 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-001052-39)
    • 25 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top